These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

663 related items for PubMed ID: 25728729

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. 2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population.
    Cho YK, Jung CH, Kang YM, Hwang JY, Kim EH, Yang DH, Kang JW, Park JY, Kim HK, Lee WJ.
    J Am Heart Assoc; 2016 Aug 19; 5(8):. PubMed ID: 27543305
    [Abstract] [Full Text] [Related]

  • 43. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis.
    Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ.
    Atherosclerosis; 2015 Aug 19; 241(2):450-4. PubMed ID: 26074319
    [Abstract] [Full Text] [Related]

  • 44. Comparison of Five Major Guidelines for Statin Use in Primary Prevention in a Contemporary General Population.
    Mortensen MB, Nordestgaard BG.
    Ann Intern Med; 2018 Jan 16; 168(2):85-92. PubMed ID: 29297004
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.
    Waite LH, Phan YL, Spinler SA.
    J Am Pharm Assoc (2003); 2016 Jan 16; 56(3):284-92. PubMed ID: 27156942
    [Abstract] [Full Text] [Related]

  • 49. Risk score overestimation: the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort.
    DeFilippis AP, Young R, McEvoy JW, Michos ED, Sandfort V, Kronmal RA, McClelland RL, Blaha MJ.
    Eur Heart J; 2017 Feb 21; 38(8):598-608. PubMed ID: 27436865
    [Abstract] [Full Text] [Related]

  • 50. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease.
    Karmali KN, Goff DC, Ning H, Lloyd-Jones DM.
    J Am Coll Cardiol; 2014 Sep 09; 64(10):959-68. PubMed ID: 25190228
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Hyperlipidemia: Drugs for Cardiovascular Risk Reduction in Adults.
    Last AR, Ference JD, Menzel ER.
    Am Fam Physician; 2017 Jan 15; 95(2):78-87. PubMed ID: 28084704
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations.
    Anderson TS, Wilson LM, Sussman JB.
    JAMA Intern Med; 2024 Aug 01; 184(8):963-970. PubMed ID: 38856978
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
    Mortensen MB, Tybjærg-Hansen A, Nordestgaard BG.
    JAMA Cardiol; 2022 Aug 01; 7(8):836-843. PubMed ID: 35793078
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.